Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258


The applicability and utility of immunohistochemical biomarkers in bladder pathology.

Akgul M, MacLennan GT, Cheng L.

Hum Pathol. 2020 Feb 6. pii: S0046-8177(20)30017-4. doi: 10.1016/j.humpath.2020.01.004. [Epub ahead of print]


Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded.

Samaratunga H, Delahunt B, Egevad L, Srigley JR, Billis A, Bostwick DG, Camparo P, Cheng L, Clouston D, Denham J, Furusato B, Hartmann A, Jufe L, Kench J, Kenwright DN, Kristiansen G, Leite KRM, MacLennan GT, Merrimen J, Moch H, Oxley J, Pan CC, Paner G, Ro J, Sesterhenn IAM, Shanks J, Thunders M, Tsuzuki T, Wheeler T, Yaxley JW, Varma M.

Pathology. 2020 Feb;52(2):192-196. doi: 10.1016/j.pathol.2019.11.001. Epub 2019 Dec 14. Review.


Five decades of urologic pathology: the accelerating expansion of knowledge in renal cell neoplasia.

MacLennan GT, Cheng L.

Hum Pathol. 2020 Jan;95:24-45. doi: 10.1016/j.humpath.2019.09.009. Epub 2019 Oct 23.


Distinct mutational landscape of inverted urothelial papilloma.

Akgul M, MacLennan GT, Cheng L.

J Pathol. 2019 Sep;249(1):3-5. doi: 10.1002/path.5307. Epub 2019 Jul 2.


Differentially Expressed Genes and Molecular Pathways in an Autochthonous Mouse Prostate Cancer Model.

Verma S, Shukla S, Pandey M, MacLennan GT, Gupta S.

Front Genet. 2019 Mar 26;10:235. doi: 10.3389/fgene.2019.00235. eCollection 2019.


Ser-486/491 phosphorylation and inhibition of AMPKα activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.

Babcook MA, Akgul M, Margevicius S, MacLennan GT, Fu P, Abouassaly R, Gupta S.

Prostate. 2018 Jul;78(10):714-723. doi: 10.1002/pros.23515. Epub 2018 Mar 26.


Chest wall toxicity after hypofractionated proton beam therapy for liver malignancies.

Yeung R, Bowen SR, Chapman TR, MacLennan GT, Apisarnthanarax S.

Pract Radiat Oncol. 2018 Jul - Aug;8(4):287-293. doi: 10.1016/j.prro.2017.12.007. Epub 2017 Dec 24.


Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.

Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R.

Mod Pathol. 2018 Jan;31(1):24-38. doi: 10.1038/modpathol.2017.104. Epub 2017 Nov 17. Review.


Influence of chronic inflammation on Bcl-2 and PCNA expression in prostate needle biopsy specimens.

Glover M, Soni S, Ren Q, Maclennan GT, Fu P, Gupta S.

Oncol Lett. 2017 Oct;14(4):3927-3934. doi: 10.3892/ol.2017.6668. Epub 2017 Jul 26.


Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation.

Caliò A, Eble JN, Hes O, Martignoni G, Harari SE, Williamson SR, Brunelli M, Osunkoya AO, Wang L, Comperat E, Lopez-Beltran A, Wang M, Zhang S, Curless KL, Post KM, Chang HY, Luchini C, Baldrige LA, MacLennan GT, Montironi R, Grignon DJ, Cheng L.

Oncotarget. 2016 Aug 8;8(33):54096-54105. doi: 10.18632/oncotarget.11117. eCollection 2017 Aug 15.


Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.

Priemer DS, Wang M, Zhang S, Lopez-Beltran A, Kouba E, Montironi R, Davidson DD, MacLennan GT, Wang L, Osunkoya AO, Deng Y, Emerson RE, Cheng L.

Eur Urol Focus. 2018 Dec;4(6):880-888. doi: 10.1016/j.euf.2017.03.007. Epub 2017 Mar 31.


Fluorescence in situ hybridization in surgical pathology: principles and applications.

Cheng L, Zhang S, Wang L, MacLennan GT, Davidson DD.

J Pathol Clin Res. 2017 Feb 23;3(2):73-99. doi: 10.1002/cjp2.64. eCollection 2017 Apr. Review.


TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.

Wang X, Lopez-Beltran A, Osunkoya AO, Wang M, Zhang S, Davidson DD, Emerson RE, Williamson SR, Tan PH, Kaimakliotis HZ, Baldridge LA, MacLennan GT, Montironi R, Cheng L.

Future Oncol. 2017 Apr;13(8):705-714. doi: 10.2217/fon-2016-0414. Epub 2017 Jan 5.


Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the NAB2-STAT6 fusion gene.

Kouba E, Simper NB, Chen S, Williamson SR, Grignon DJ, Eble JN, MacLennan GT, Montironi R, Lopez-Beltran A, Osunkoya AO, Zhang S, Wang M, Wang L, Tran T, Emerson RE, Baldrige LA, Monn MF, Linos K, Cheng L.

J Clin Pathol. 2017 Jun;70(6):508-514. doi: 10.1136/jclinpath-2016-204088. Epub 2016 Oct 31.


TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.

Fisher KW, Zhang S, Wang M, Montironi R, Wang L, Baldrige LA, Wang JY, MacLennan GT, Williamson SR, Lopez-Beltran A, Cheng L.

Mol Carcinog. 2017 Mar;56(3):814-820. doi: 10.1002/mc.22535. Epub 2016 Aug 31.


Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in a mouse model.

He Q, Babcook MA, Shukla S, Shankar E, Wang Z, Liu G, Erokwu BO, Flask CA, Lu L, Daneshgari F, MacLennan GT, Gupta S.

Prostate. 2016 Aug;76(11):964-76. doi: 10.1002/pros.23185. Epub 2016 Apr 4.


Extravesical Pagetoid Spread of Urothelial Carcinoma in Situ. A Report of Five Cases.

Akgul M, Bomeisl PB, MacLennan GT.

Anal Quant Cytopathol Histpathol. 2015 Dec;37(6):364-8.


Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.

Cheng L, Davidson DD, Wang M, Lopez-Beltran A, Montironi R, Wang L, Tan PH, MacLennan GT, Williamson SR, Zhang S.

Histopathology. 2016 Jul;69(1):107-13. doi: 10.1111/his.12920. Epub 2016 Feb 11.


Apigenin blocks IKKα activation and suppresses prostate cancer progression.

Shukla S, Kanwal R, Shankar E, Datt M, Chance MR, Fu P, MacLennan GT, Gupta S.

Oncotarget. 2015 Oct 13;6(31):31216-32. doi: 10.18632/oncotarget.5157.


Inflammatory Signaling Involved in High-Fat Diet Induced Prostate Diseases.

Shankar E, Bhaskaran N, MacLennan GT, Liu G, Daneshgari F, Gupta S.

J Urol Res. 2015 Jan 1;2(1). pii: 1018. Epub 2015 Jan 12.


Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links.

He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):7-13. doi: 10.1038/pcan.2015.43. Epub 2015 Sep 22. Review.


Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice.

Shukla S, Shankar E, Fu P, MacLennan GT, Gupta S.

PLoS One. 2015 Sep 17;10(9):e0138710. doi: 10.1371/journal.pone.0138710. eCollection 2015.


Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma.

Kinney SN, Eble JN, Hes O, Williamson SR, Grignon DJ, Wang M, Zhang S, Baldrige LA, Martignoni G, Brunelli M, Wang L, Comperat E, Fan R, Montironi R, MacLennan GT, Cheng L.

Mod Pathol. 2015 Sep;28(9):1236-48. doi: 10.1038/modpathol.2015.81. Epub 2015 Aug 7.


Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR.

Simper NB, Jones CL, MacLennan GT, Montironi R, Williamson SR, Osunkoya AO, Wang M, Zhang S, Grignon DJ, Eble JN, Tran T, Wang L, Baldrige LA, Cheng L.

Hum Pathol. 2015 Jun;46(6):805-12. doi: 10.1016/j.humpath.2015.02.004. Epub 2015 Feb 26.


Testicular Adnexal Smooth Muscle Hyperplasia: A Mimic of Malignancy.

Akgul M, Elliott RM, Paspulati R, MacLennan GT.

J Urol. 2015 Jul;194(1):207-8. doi: 10.1016/j.juro.2015.04.020. Epub 2015 Apr 11. No abstract available.


Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor.

Li H, Hes O, MacLennan GT, Eastwood DC, Iczkowski KA.

Virchows Arch. 2015 May;466(5):581-8. doi: 10.1007/s00428-015-1732-9. Epub 2015 Feb 19.


Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations.

Choi E, Williamson SR, Montironi R, Zhang S, Wang M, Eble JN, Grignon DJ, Lopez-Beltran A, Idrees MT, Baldridge LA, Scarpelli M, Jones CL, Wang L, MacLennan GT, Osunkoya AO, Cheng L.

Histopathology. 2015 Jul;67(1):20-38. doi: 10.1111/his.12619. Epub 2015 Jan 29.


Small cell carcinoma of the prostate: molecular basis and clinical implications.

Wang L, Davidson DD, Montironi R, Lopez-Beltran A, Zhang S, Williamson SR, MacLennan GT, Wang C, Wang M, Emerson RE, Du X, Cheng L.

Histol Histopathol. 2015 Apr;30(4):413-24. doi: 10.14670/HH-30.413. Epub 2014 Nov 10. Review.


Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.

Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, Comperat EM, Datta MW, Evans AG, Griffiths DF, Guo CC, Hailemariam S, Huang W, Humphrey PA, Jiang Z, Kahane H, Kristiansen G, La Rosa FG, Lopez-Beltran A, MacLennan GT, Magi-Galluzzi C, Merrimen J, Montironi R, Osunkoya AO, Picken MM, Rao N, Shah RB, Shanks JH, Shen SS, Tawfik OW, True LD, Van der Kwast T, Varma M, Wheeler TM, Zynger DL, Sahr N, Bostwick DG.

Ann Diagn Pathol. 2014 Dec;18(6):333-42. doi: 10.1016/j.anndiagpath.2014.08.010. Epub 2014 Sep 3.


Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.

Babcook MA, Shukla S, Fu P, Vazquez EJ, Puchowicz MA, Molter JP, Oak CZ, MacLennan GT, Flask CA, Lindner DJ, Parker Y, Daneshgari F, Gupta S.

Mol Cancer Ther. 2014 Oct;13(10):2288-302. doi: 10.1158/1535-7163.MCT-14-0451. Epub 2014 Aug 13.


Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.

Wang L, Williamson SR, Zhang S, Huang J, Montironi R, Davison DD, Wang M, Yao JL, Lopez-Beltran A, Osunkoya AO, MacLennan GT, Baldridge LA, Du X, Cheng L.

Mol Carcinog. 2015 Sep;54(9):900-7. doi: 10.1002/mc.22162. Epub 2014 Apr 29.


Cystic partially regressed clear cell renal cell carcinoma: a potential mimic of multilocular cystic renal cell carcinoma.

Williamson SR, MacLennan GT, Lopez-Beltran A, Montironi R, Tan PH, Martignoni G, Grignon DJ, Eble JN, Idrees MT, Scarpelli M, Cheng L.

Histopathology. 2013 Dec;63(6):767-79. doi: 10.1111/his.12239. Epub 2013 Oct 7.


Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.

Shukla S, Bhaskaran N, Babcook MA, Fu P, Maclennan GT, Gupta S.

Carcinogenesis. 2014 Feb;35(2):452-60. doi: 10.1093/carcin/bgt316. Epub 2013 Sep 25.


EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder.

Alexander RE, Montironi R, Lopez-Beltran A, Williamson SR, Wang M, Post KM, Sen JD, Arnold AK, Zhang S, Wang X, Koch MO, Hahn NM, Masterson TA, MacLennan GT, Davidson DD, Compérat E, Cheng L.

Mod Pathol. 2014 Jan;27(1):107-12. doi: 10.1038/modpathol.2013.132. Epub 2013 Jul 26.


Atypical adenomatous hyperplasia of prostate lacks TMPRSS2-ERG gene fusion.

Cheng L, Davidson DD, Maclennan GT, Lopez-Beltran A, Montironi R, Wang M, Tan PH, Baldridge LA, Zhang S.

Am J Surg Pathol. 2013 Oct;37(10):1550-4. doi: 10.1097/PAS.0b013e318294e9bc.


Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.

Schelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J, Montironi R, Lopez-Beltran A, Emerson RE, Idrees MT, Osunkoya AO, Man YG, Maclennan GT, Baldridge LA, Compérat E, Cheng L.

Hum Pathol. 2013 Oct;44(10):2227-33. doi: 10.1016/j.humpath.2013.05.005. Epub 2013 Jul 12.


The trigger-maintenance model of persistent mild to moderate hyperoxaluria induces oxalate accumulation in non-renal tissues.

Marengo SR, Zeise BS, Wilson CG, MacLennan GT, Romani AM.

Urolithiasis. 2013 Nov;41(6):455-66. doi: 10.1007/s00240-013-0584-5. Epub 2013 Jul 3.


Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features.

Williamson SR, Bunde PJ, Montironi R, Lopez-Beltran A, Zhang S, Wang M, Maclennan GT, Cheng L.

Am J Surg Pathol. 2013 Oct;37(10):1619-26. doi: 10.1097/PAS.0b013e318293729d.


Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice.

Shukla S, Bhaskaran N, Maclennan GT, Gupta S.

Prostate. 2013 Oct;73(14):1507-17. doi: 10.1002/pros.22698. Epub 2013 Jun 13.


Human papillomavirus is not an etiologic agent of urothelial inverted papillomas.

Alexander RE, Davidson DD, Lopez-Beltran A, Montironi R, MacLennan GT, Compérat E, Idrees MT, Emerson RE, Cheng L.

Am J Surg Pathol. 2013 Aug;37(8):1223-8. doi: 10.1097/PAS.0b013e3182863fc1.


TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.

Rao Q, Williamson SR, Zhang S, Eble JN, Grignon DJ, Wang M, Zhou XJ, Huang W, Tan PH, Maclennan GT, Cheng L.

Am J Surg Pathol. 2013 Jun;37(6):804-15. doi: 10.1097/PAS.0b013e31827e17cb.


Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.

Bradish JR, Montironi R, Lopez-Beltran A, Post KM, MacLennan GT, Cheng L.

Future Oncol. 2013 Feb;9(2):245-53. doi: 10.2217/fon.12.179. Review.


Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression.

Shukla S, Sharma H, Abbas A, MacLennan GT, Fu P, Danielpour D, Gupta S.

PLoS One. 2013;8(1):e53527. doi: 10.1371/journal.pone.0053527. Epub 2013 Jan 7.


Anatomic, morphologic and genetic heterogeneity of prostate cancer: implications for clinical practice.

Cheng L, MacLennan GT, Lopez-Beltran A, Montironi R.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1371-4. doi: 10.1586/era.12.127. No abstract available.


Image-guided biopsy of small renal masses in the era of ablative therapies.

Salem S, Ponsky LE, Abouassaly R, Cherullo EE, Isariyawongse JP, Maclennan GT, Nakamoto D, Haaga JR.

Int J Urol. 2013 Jun;20(6):580-4. doi: 10.1111/iju.12010. Epub 2012 Nov 27.


Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma.

Williamson SR, Halat S, Eble JN, Grignon DJ, Lopez-Beltran A, Montironi R, Tan PH, Wang M, Zhang S, Maclennan GT, Baldridge LA, Cheng L.

Am J Surg Pathol. 2012 Oct;36(10):1425-33.


Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1.

Kanwal R, Pandey M, Bhaskaran N, Maclennan GT, Fu P, Ponsky LE, Gupta S.

Mol Carcinog. 2014 Jan;53(1):8-18. doi: 10.1002/mc.21939. Epub 2012 Jul 25.


KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas.

Alexander RE, Lopez-Beltran A, Montironi R, MacLennan GT, Post KM, Bilbo SA, Jones TD, Huang W, Rao Q, Sen JD, Meehan K, Cornwell A, Miravalle L, Cheng L.

Histopathology. 2012 Dec;61(6):1036-42. doi: 10.1111/j.1365-2559.2012.04309.x. Epub 2012 Jul 17.


p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma.

Alexander RE, Hu Y, Kum JB, Montironi R, Lopez-Beltran A, Maclennan GT, Idrees MT, Emerson RE, Ulbright TM, Grignon DG, Eble JN, Cheng L.

Mod Pathol. 2012 Nov;25(11):1526-33. doi: 10.1038/modpathol.2012.103. Epub 2012 Jun 8.


Evidence for clonal fibroblast proliferation and autoimmune process in idiopathic retroperitoneal fibrosis.

Clevenger JA, Wang M, MacLennan GT, Montironi R, Lopez-Beltran A, Cheng L.

Hum Pathol. 2012 Nov;43(11):1875-80. doi: 10.1016/j.humpath.2012.01.012. Epub 2012 May 4.


Supplemental Content

Loading ...
Support Center